Instil Bio, Inc. is a clinical-stage biotechnology company focused on the development of innovative cell therapies for the treatment of cancer. Specializing within the pharmaceuticals and biotech sector, the company’s primary function is to research and advance next-generation immunotherapies, particularly those designed to harness and enhance patients’ own immune systems to target solid tumors. Instil Bio is notable for its work on tumor-infiltrating lymphocyte (TIL) therapies, as well as its proprietary bispecific antibody platforms. A key pipeline candidate, AXN-2510, is a PD-L1xVEGF bispecific antibody currently advancing through clinical trials, targeting relapsed or refractory solid tumors and non-small cell lung cancer (NSCLC). Founded in 2018, Instil Bio’s efforts impact the global healthcare market by seeking novel approaches to address cancers with unmet medical needs. The company’s research contributes to advancements in oncology and immunotherapy, sectors that are critical to the broader medical research and biopharmaceutical landscape. Instil Bio occupies a unique position among biotechnology peers, leveraging cutting-edge science to drive potential therapeutic breakthroughs in cancer care.